PUBLICATIONS:


20. Menter A. Psoriasis and disorders that mimic it. Diagnosis 1985; 7:139-152.


108. Cather JC, Menter A. Vesicular eruption including the mouth. BUMC. 2002; 93-94.


143. Menter A. Understanding and using the new biologics. Skin & Aging. 2004 Feb; Suppl 4-5.


197. Menter, A. Topical Monotherapy With Clobetasol Propionate Spray 0.05% Added to Other Stable Treatments: Add-on Therapy in the COBRA Trial. *Cutis* 2007 Nov Vol.80 5S


211. Menter A, Vamvakis G, Jorizzo J. One-Week Treatment With Once-Daily Fluorouracil Cream 0.5% in Participants With Actinic Keratoses. *Cutis.* 2008; 81:509-516


227. Menter A, Abramovits W, Colon LE, Johnson LA, Gottschalk RW. Comparing Clobetasol, Propionate 0.05% Spray to Calcipotriene 0.005% Betamethasone Dihydropropionate 0.064% Ointment for the Treatment of Moderate to Severe Plaque Psoriasis *J Dr Dermatol 2009 Jan;8(1):52-7*


229. Ul Ain Kamili Q, Menter A. Psoriasis in the Pediatric Patient. *Pediatric Society of Greater Dallas, First Quarter, Feb 2009, Pg 10-14*


239. ul Ain Kamili Q, Menter A. Genetics of psoriasis and psoriatic arthritis. *Psoriasis Forum, vol 15, No 1: 8-12*


Alan Menter, MD – CV

26

255. Menter A, Griffiths CEM, Tebbey PW, Horn EJ, Sterry W on behalf of the International Psoriasis Council. Exploring the association between cardiovascular and other disease related risk factors in the psoriasis population: the need for increased understanding across the medical community. JEADV 2010


272. Dhaliwal S, Patel M, Menter A. Secondary syphilis and HIV. *Proc (Baylor Univ Med Cent).* 2012 Jan;25(1):87-9


279. Menter A. Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis. Cuts. 2012 Feb;89(2):89-94


Alan Menter, MD – CV
29


